ICON Announces Release of ADDPLAN® neo
DUBLIN--(BUSINESS WIRE)--(NASDAQ: ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced the release of ADDPLAN® neo, providing an advanced validated integrated technology platform for design, simulation and analysis of adaptive clinical trials.
The new release combines ADDPLAN® BASE, ADDPLAN® MC (for Multiple Comparison Designs) and ADDPLAN® DF (for dose ranging and dose finding trials using MCP-Mod methodology) modules under one umbrella, increasing simulation speed for each application and allowing computation of multiple projects on one, integrated robust framework. The software has been rewritten using C programming language to ensure efficient usage of computing resources and fast simulation results.
Following feedback from customers, ICON enhanced the algorithms’ stability and speed and added new features such as the ability to incorporate custom R code in the ADDPLAN® neo Dose Finding module.
Additional ADDPLAN® neo features include:
- Every-Phase Capabilities – Strengthen and advance study design, simulation and analysis for every phase of drug development, including Adaptive MCP-Mod, critical for dose-finding designs.
- Improved User Experience – A fully validated, graphical user interface (GUI) software, ADDPLAN® neo features a quick access to adaptive approaches across all phases of drug development.
Andrew Garrett, EVP Scientific Operations said “With the recent FDA announcement of its Complex Innovative Designs Pilot Meeting Program, targeted at innovative trial designs to inform regulatory decision making, the door is very much open for adaptive and other types of innovative design. ADDPLAN® neo provides an integrated and increasingly flexible solution that truly supports this innovation agenda by providing a validated tool that helps convert theory to practice.”
About ICON plc
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,675 employees.
Further information is available at www.iconplc.com/addplanneo
Contacts
ICON Media Contact
Lucinda Sandon-Allum
Weber Shandwick
+44 (0)20 7067 0548
lsandon-allum@webershandwick.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
